Humoral and cellular immunity in convalescent COVID-19 people with multiple sclerosis treated with ofatumumab.

Authors:
Adamec I; Rogić D; Penz MG; Braun C; Habek M.

Journal:
J Neuroimmunol

Publication Year: 2021

DOI:
10.1016/j.jneuroim.2021.577788

PMCID:
PMC8667348

PMID:
34922128

View on PubMed View on PMC View Publisher
Journal Information

Full Title: J Neuroimmunol

Abbreviation: J Neuroimmunol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Allergy and Immunology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Central nervous system (CNS) inflammatory demyelinating diseases (IDDs) associated with COVID-19: A…
Feizi P; Sharma K; Pasham SR and 4 more (2022) - Transparency Score: 3/6
Myelin oligodendrocyte glycoprotein-IgG associated disorders (MOGAD) following SARS-CoV-2 infection…
Lambe J; McGinley MP; Moss BP and 5 more (2022) - Transparency Score: 1/6
A case of longitudinally extensive transverse myelitis following vaccination against Covid-19.
Pagenkopf C; Südmeyer M. (2021) - Transparency Score: 2/6
A systematic review of cases of CNS demyelination following COVID-19 vaccination.
Ismail II; Salama S. (2021) - Transparency Score: 3/6
Complex movement disorders in SARS-CoV-2 infection induced acute disseminated encephalomyelitis.
Ghosh R; Dubey S; Mandal A and 2 more (2021) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
2/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"DR: Reports no conflict of interest."

Evidence found in paper:

"Funding This study was funded by Novartis Pharma AG, Basel, Switzerland."

Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025